Abstract
There is initial evidence, at least in cardiac surgery, that total intra-venous anesthesia (usually a propofol-based total intravenous anesthesia) is associated with an increased mortality when compared to an anesthetic plan including a halogenated anesthetics. The cardiac protective properties of halogenated agents (desflurane, isoflurane and sevoflurane) have not been confirmed in non-cardiac surgery and mixed results exist for patients admitted in postoperative intensive care units. This article summarizes the papers with the most impressive findings in favor of halogenated anesthetics, but it recognizes that, at the same time, there is no evidence based medicine against the use of propofol, highlighting the need for large randomized trials that should focus on survival.
Keywords: Anesthesia, cardiac surgery, mortality, propofol, halogenated agents, desflurane, isoflurane, sevoflurane.
Current Pharmaceutical Design
Title:Is Time to Change to Halogenated Drugs in Cardiac Surgery, What do we have to do with Propofol?
Volume: 20 Issue: 34
Author(s): Giovanni Landoni, Laura Pasin, Giovanni Borghi and Alberto Zangrillo
Affiliation:
Keywords: Anesthesia, cardiac surgery, mortality, propofol, halogenated agents, desflurane, isoflurane, sevoflurane.
Abstract: There is initial evidence, at least in cardiac surgery, that total intra-venous anesthesia (usually a propofol-based total intravenous anesthesia) is associated with an increased mortality when compared to an anesthetic plan including a halogenated anesthetics. The cardiac protective properties of halogenated agents (desflurane, isoflurane and sevoflurane) have not been confirmed in non-cardiac surgery and mixed results exist for patients admitted in postoperative intensive care units. This article summarizes the papers with the most impressive findings in favor of halogenated anesthetics, but it recognizes that, at the same time, there is no evidence based medicine against the use of propofol, highlighting the need for large randomized trials that should focus on survival.
Export Options
About this article
Cite this article as:
Landoni Giovanni, Pasin Laura, Borghi Giovanni and Zangrillo Alberto, Is Time to Change to Halogenated Drugs in Cardiac Surgery, What do we have to do with Propofol?, Current Pharmaceutical Design 2014; 20 (34) . https://dx.doi.org/10.2174/1570161112666140123105536
DOI https://dx.doi.org/10.2174/1570161112666140123105536 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coronary Angiography Using Noninvasive Imaging Techniques of Cardiac CT and MRI
Current Cardiology Reviews Crucial Role of Interferon-γ and Stimulated Macrophages in Cardiovascular Disease
Current Vascular Pharmacology The Impact of CRISPR/Cas9-Based Genomic Engineering on Biomedical Research and Medicine
Current Molecular Medicine Editorial: The Interplay between TSH and Lipids. What Should Clinicians Know?
Current Vascular Pharmacology Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Colchicine in Coronary Artery Disease: An Old Acquaintance in New Attire?
Current Medicinal Chemistry Investigating the Associations between Mediterranean Diet, Physical Activity and Living Environment with Childhood Asthma using Path Analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part I: (Patho)-Physiology, Rationale and Perspective on Pulse Pressure Amplification
Current Pharmaceutical Design Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design Osteoprotegerin and Diabetes-Associated Pathologies
Current Molecular Medicine Editorial: [Hot Topic: Establishment of the Australian Infectious Diseases Research Centre]
Current Drug Targets Development of Functional Dark Chocolate by Incorporating Flaxseed (Linum usitatissimum) Oil and Honey with Improved Organoleptic and Textural Attributes
Current Nutrition & Food Science Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm
Current Alzheimer Research Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets The Role of Autophagy on the Survival of Dopamine Neurons
Current Topics in Medicinal Chemistry Inhibitory Effect of Copper on Cystathionine β-Synthase Activity: Protective Effect of an Analog of the Human Albumin N-Terminus
Protein & Peptide Letters Cardioprotective Properties of HDL: Structural and Functional Considerations
Current Medicinal Chemistry Effects and Perspectives of Chinese Patent Medicines for Tonifying <i>Qi</i> and Promoting Blood Circulation on Patients with Cerebral Infarction
Current Vascular Pharmacology Phytotherapy for the Prevention of Atherosclerosis-Associated Early Cerebral Ischemia
Current Drug Metabolism Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews